WASHINGTON, D.C. (December 2, 2015)—A new study focusing on health outcomes for patients subject to the competitive bidding program using diabetic testing products finds that the program led to adverse health outcomes, including higher inpatient costs as well as increased hospitalization and death, for diabetic Medicare beneficiaries. The report also criticizes CMS for their evaluation of the program and their failure to show the true impact the bidding program has on Medicare beneficiaries.
diabetes
HME providers will see more diabetic seniors in the years to come. Understand the myriad health complications they face to help them stay active and independent.
Many manufacturers and providers are already making plans to participate in the fall Medtrade show in Atlanta, following completion of Medtrade Spring April 10-12, organizers reported last week.
“We believe in the show,” Ron Resnick, president of Blue Chip Medical of New York, told Medtrade officials. “We think the dealers who are going to survive the challenges are the ones who will be there. It’s not just a trade show anymore. It’s a meeting place.”
Competitive bidding rattles the diabetic HME supply market.